Immuron Ltd News

Immuron Says Jeannie Joughin Was Appointed to Board >IMRN

Immuron Says Jeannie Joughin Was Appointed to Board >IMRN

Dow JonesMay 31 18:02

Immuron Says Roger Aston Has Resigned From Board of Directors

Immuron Says Roger Aston Has Resigned From Board of Directors

Dow JonesMay 31 18:01

Immuron Limited Announces Board Reshuffle

Immuron Limited (AU:IMC) has released an update.

TipRanksMay 31 10:38

Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%

Immuron (ASX:IMC) saw a 51% surge in global sales in the March quarter compared with the prior comparative period, driven by a strong performance of its Travelan product in Australia, according to a W

MT NewswiresApr 10 09:46

ADRs Close Lower, Immuron Ltd. Declines 17.1%

This article was automatically generated by Dow Jones Newswires using technology from Automated Insights. International stocks trading in New York closed lower on Monday, as the S&P/BNY Mellon index

Dow JonesMar 12 04:50

We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate

Yahoo FinanceMar 9 04:47

Immuron Shares Soar Premarket on Positive Travelan Study

By Colin Kellaher U.S.-listed shares of Immuron more than doubled in premarket trading Thursday after the biopharmaceutical company reported positive results from a Phase 2 study of its Travelan prod

WSJMar 7 19:37

Immuron Moving Anti-Diarrhea Drug to Phase Three Trials

Immuron (ASX:IMC) confirmed the efficacy of its single-dose Travelan drug in preventing moderate to severe diarrhea induced by Escherichia coli (E. coli) bacteria, the company said in a Wednesday fili

MT NewswiresMar 7 16:41

Immuron's Travelan Immune Supplement Registers AU$2.7 Million Sales in YTD January

Immuron (ASX:IMC) said sales of its Travelan immune supplement reached AU$2.7 million in the year to date ending January, a Tuesday filing said. Sales of the over-the-counter immune supplement for pat

MT NewswiresFeb 13 11:06

Press Release: Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Immuron CEO, Steven Lydeamore Investor Webinar Presentation MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrat

Dow JonesFeb 8 19:00

Immuron Posts Record Travelan Sales in Fiscal H1

Immuron (ASX:IMC) reported record sales of AU$2.3 million from its over-the-counter gastrointestinal and digestive health immune supplement Travelan for the first half of fiscal year 2024. This brough

MT NewswiresJan 16 13:00

Immuron Reports Big Jump in Fiscal Q1 Travelan Sales

Immuron (ASX:IMC) reported a big jump in Travelan sales in the fiscal first quarter ended June. Sales jumped year over year to AU$1.6 million in fiscal Q1, up AU$1.5 million from the year-ago quarter'

MT NewswiresOct 11, 2023 16:55

Immuron Sees Nearly 8000% Boost in August Sales of Gastrointestinal Drug

Sales of Immuron's (ASX:IMC) gastrointestinal and digestive health supplement Travelan rose by a substantial 7984% in August to around AU$1.2 million from AU$14,581 during the year-ago period. The pos

MT NewswiresSep 14, 2023 18:51

Planet MicroCap Review Magazine for Summer 2023 Now Online

LOS ANGELES, CA / ACCESSWIRE / August 23, 2023 / Planet MicroCap, a global multimedia financial news and publishing company that focuses on delivering news, information, data and analytics for publicl

AccesswireAug 23, 2023 20:30

Immuron Secures Clearance for Packaging of Immunotherapy Product; Shares Surge 27%

Immuron (ASX:IMC) secured a good manufacturing practice clearance from the Australian medical regulator Therapeutic Goods Administration related to the packaging used for the biopharmaceutical firm's

MT NewswiresAug 9, 2023 13:52

Immuron Ltd Owned Ateria Health Launches Juvia in Australia

Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the tr

BenzingaJul 11, 2023 18:06

Immuron FY23 Sales A$1.80M >IMRN

Immuron FY23 Sales A$1.80M >IMRN

Dow JonesJul 5, 2023 18:02

Immuron FY23 Sales Increase 136% on FY22 Sales

MELBOURNE, Australia, July 05, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce FY23 sales (unaudited net sales) results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan and Protectyn.

GlobeNewswireJul 5, 2023 18:00

Immuron Limited Announces Participation in the LD Micro Invitational XIII

Melbourne, Australia--(Newsfile Corp. - May 16, 2023) - Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset

newsfileMay 16, 2023 19:30